Cooper Companies had impressive Q3 results for both its CooperVision and CooperSurgical divisions and managed an all-around beat. Despite macroeconomic challenges such as currency, inflation, and supply chain issues negatively affecting profitability, the company continues to take share and drive sustainable top-line growth. CooperVision experienced strong and diversified growth in all product categories, with its Daily Silicone hydrogel portfolio and myopia management products leading the way. The company is launching MyDay Energys and expanding its MyDay toric parameter range while also increasing the production of Biofinity lenses. The company’s growth in the myopia management market has been strong, with revenues up 42%, and it remains a market leader with its FDA-approved MiSight product. However, COVID-19 restrictions in China have impacted sales of all contact lenses, including MiSight and Ortho-K products. We give the company a ‘Hold’ rating with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!